Investigating the effects of Griffonia simplicifolia on pain and sensitization in healthy volunteers
The Effect of Griffonia Simplicifolia on Pain Intensity, Central and Peripheral Sensitization, Painmodulation in Healthy Volunteers - A Randomized, Double-blinded, Placebo-controlled, Cross-over Study
NA · Medical University of Graz · NCT06893822
This study is testing if a natural supplement called Griffonia simplicifolia can help reduce pain and sensitivity in healthy people.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Medical University of Graz (other) |
| Locations | 1 site (Graz) |
| Trial ID | NCT06893822 on ClinicalTrials.gov |
What this trial studies
This interventional study utilizes a randomized, placebo-controlled cross-over design to evaluate the effects of Griffonia simplicifolia, which contains the serotonin precursor 5-hydroxytryptophan (5-HTP), on pain intensity and sensitization mechanisms in healthy individuals. The study aims to explore how 5-HTP influences both peripheral and central sensitization, as well as descending inhibitory pathways, using Quantitative Sensory Testing (QST). By examining these effects, the research seeks to provide insights into the analgesic efficacy of 5-HTP and its potential applications in chronic pain management.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy volunteers without chronic pain or significant medical conditions.
Not a fit: Patients with chronic pain, neurological disorders, or those taking certain medications like antidepressants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the treatment of chronic pain conditions through the modulation of serotonin levels.
How similar studies have performed: Previous studies have shown some efficacy of 5-HTP in chronic pain conditions, but this specific approach in a human experimental pain model is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Exclusion Criteria: * pregnancy or breastfeeding. * renal or hepatic insufficiency * neurological/dermatological/cardiovascular diseases * chronic pain and/or use of analgesics * intake of antidepressants * intake of MAO inhibitors * intake of sleep medication * intake of St. John's wort * allergy to Griffonia simplicifolia
Where this trial is running
Graz
- Medical University of Graz — Graz, Austria (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Pain, Central Sensitisation, Peripheral Sensitization, Neuroinflammatory Response, Griffonia simplicifolia, 5-HTP, Peripheral Sensitisation